Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Accumulated Expenses data on file, last reported at $6.9 million in Q1 2026.

• Quarterly Accumulated Expenses rose 134.1% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 134.1% YoY) and the FY2025 annual result came in at $6.5 million, down 52.25% from the prior year.
• Accumulated Expenses fell to $6.9 million in Q1 2026, from $7.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $21.7 million in Q1 2022 to a low of $2.6 million in Q4 2022.
• A 5-year average of $9.0 million and a median of $6.5 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses soared 184.81% — and 2024, when it plunged 80.84%.
• Tracing ENTA's Accumulated Expenses over 5 years: stood at $2.6 million in 2022, then jumped by 66.22% to $4.3 million in 2023, then fell by 5.03% to $4.1 million in 2024, then jumped by 85.07% to $7.6 million in 2025, then decreased by 9.45% to $6.9 million in 2026.
• The last three Accumulated Expenses figures came in at $6.9 million (Q1 2026), $7.6 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.